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Introduction
Cytokine storm–mediated organ injury continues to dominate current thinking as the primary
mechanism for coronavirus disease 2019 (COVID-19). Although there is an initial hyper-inflammatory
phase, mounting evidence suggests that virus-induced defective host immunity may be the real
cause of death in many patients.1,2
COVID-19 has been called a serial lymphocyte killer because profound and protracted
lymphopenia is a near uniform finding among patients with severe COVID-19 and correlates with
morbidity and mortality.1,3 Autopsies demonstrate a devastating depletion of lymphocytes in the
spleen and other organs.2 CD4, CD8, and natural killer cells, which play important antiviral roles, are
depleted and have reduced function, leading to immune collapse.1
Clinical and pathological findings in patients with COVID-19 indicate that immunosuppression is
a critical determinant of outcomes. Secondary hospital-acquired infections occur in 50% of patients
who die.1 Cell inclusion bodies, consistent with viral persistence, have been found in lungs, kidneys,
and other organs.1,2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific
quantitative polymerase chain reaction has revealed viral load in the lungs of most patients at
autopsy, consistent with an inability to eliminate the pathogen.1,2 Collectively, these studies indicate
that impaired immune competence is an important pathogenic mechanism in COVID-19.
Interleukin 7 (IL-7) is a pleiotropic cytokine essential for lymphocyte survival and expansion.4,5
Administration of IL-7 invariably increases circulating and tissue lymphocytes and has been
administered to more than 450 patients with an excellent safety profile.4,5 IL-7 is currently in multiple
randomized clinical trials for oncologic and infectious disorders, and a trial in the United Kingdom is
evaluating its use among patients with severe COVID-19. Importantly, IL-7 has documented efficacy
as an antiviral agent.4,5 IL-7 therapy has been shown to restore lymphocyte counts and functional
activity, leading to decreased viral load and clinical improvement in several life-threating viral
infections.4,5 It has been shown to increase CD4 and CD8 T-cells 3-fold, to improve T-cell activation,
to not increase proinflammatory cytokines, and to be well tolerated in patients with bacterial sepsis.6
Thus, a compelling scientific rationale exists for examining whether IL-7 is associated with restored
host protective immunity in patients with COVID-19 and immunosuppression and improve
outcomes.1
Methods
In this case series, IL-7 was approved by the Ethics Committee of St Luc University Hospital (Brussels,
Belgium) for compassionate use in 12 critically ill patients with COVID-19 and severe lymphopenia
who had 2 consecutive absolute lymphocyte counts of less than 700/μL (to convert to ×109 per
microliter, mutliply by 0.001). Patients provided written informed consent. This study followed the
Appropriate Use and Reporting of Uncontrolled Case Series in the Medical Literature reporting guideline
for case series. An initial safety dose of 3 μg/kg was followed by a dose of 10 μg/kg by intramuscular
injection twice a week for 2 weeks. A total of 13 patients with COVID-19 who received standard-of-care
treatment and were matched to severity of illness, comorbidities, and other factors were included as
a comparator control cohort to the IL-7 treatment group.
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Data were analyzed using a mixed-effects model with repeated measures and the
autoregression 1 covariance structure. The logs of the absolute lymphocyte scores were used
because they provided a better fit to the model. The associations of group, study day, and the group
by study day interaction were all significant. Statistical analyses were conducted in SAS version 9.4
(SAS Institute). Statistical significance was set at P < .05, and all tests were 2-tailed.
Results
The 12 patients in the IL-7 group had a mean (range) age of 62 (48-76) years, and 11 (92%) were men.
The 13 patients in the control group had a mean (range) age of 59 (42-83) years, and 9 (69%) were
men (Table). No observed treatment-associated adverse effects were noted, and IL-7 was well
tolerated without inducing changes in temperature, blood pressure, or PaO2:FiO2 ratio (Figure).
Plasma proinflammatory cytokines were measured before and at 7 and 24 hours after IL-7
administration to determine whether IL-7 induced hyper-cytokinemia. Administration of IL-7 was not
associated with changes in tumor necrosis factor α, IL-1β, and IL-12p70 concentrations, which were
below the level of detection at all time points in all patients. There was no consistent association of
IL-7 administration with IL-6 concentration. Overall, 3 patients (25%) had decreases in IL-6
concentrations and 2 patients (17% ) had increases in IL-6 concentration of approximately 1000 to
1500 pg/mL at 7 hours after administration of IL-7, suggesting that these changes in IL-6
concentration may have been because of changes in the underlying patient physiologic state rather
than because of IL-7. At day 30, secondary infections occurred in 7 patients (58%) in the IL-7 group
compared with 11 (85%) in the control group; 30-day mortality was 42% (5) and 46% (6),
respectively (Table). IL-7 was associated with a restored lymphocyte count, with the IL-7 group
having levels more than 2-fold greater than the control group (mean [SE], 1734/μL [227/μL] vs
885/μL [239/μL]; P = .02) (Figure).
Discussion
The findings of this study suggest that IL-7 can be safely administered to critically ill patients with




IL-7 group (n = 12) Control group (n = 13)
Age, mean (range), y 62 (48-76) 59 (42-83)
Sex
Women 1 (8) 4 (31)
Men 11 (92) 9 (69)
BMI, mean (range) 25.13 (0-33.95) 27.33 (21.42-37.37)
Comorbidities
Hypertension 6 (50) 6 (46)
Diabetes 2 (17) 2 (15)
Cardiopathy 2 (17) 2 (15)
Other 6 (50) 8 (62)
APACHE II score, mean (range) 14 (9-20) 13 (7-16)
SOFA score, mean (range) 5 (4-7) 4 (2-5)
Worst PaO2:FiO2 ratio, mean (range) 89 (49-182) 83 (54-180)
CRP at admission, mean (range), mg/dL 20.1 (0.74-42.3) 1.98 (0.33-48.0)
Time from ICU admission to intubation, mean (range), d 3 (0-8) 3 (0-9)a
Secondary infection(s) 7 (58) 11 (85)
30-day mortality 5 (42) 6 (46)
Abbreviations: APACHE, Acute Physiology and Chronic
Health Evaluation; BMI, body mass index (calculated
as weight in kilograms divided by height in meters
squared); CRP, C-reactive protein; ICU, intensive care
unit; SOFA, Sequential Organ Failure Assessment.
SI conversion factor: To convert CRP to mg/L, multiply
by 10.
a 1 of 13 patients was never intubated.
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Lymphocyte count in patients in IL-7 and control groupsA




















Lymphocyte count in survivors vs nonsurvivorsB

















Body temperature in patients in IL-7 and control groupsC















Pao2:Fio2 ratio in patients in IL-7 and control groupsD











IL-7 was administered at 3 μg/kg on day 1 and at 10
μg/kg at days 2, 5, 8, and 12. Points indicate means,
and whiskers indicate SEs.
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lymphocytes returning to a reference level, appearing to reverse a pathologic hallmark of COVID-19.
Importantly, previous studies have reported that IL-7–associated restoration of lymphocyte numbers
enhanced the activity of antiviral agents.6 A limitation of the current study is that no phenotypic or
functional studies of immune cells were conducted. Administration of IL-7 alone or in combination
with other therapies warrants serious consideration for patients with COVID-19 and evidence of
immunosuppression.
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